Symptomatology and General Principles of Treatment of Chronic Pancreatitis

1. Kebekova Aizat Ashimzhanovna

2. Pranavkumar Purushottam

3. Faizan ul Haq

(1. Lecturer, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic

2. Student, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic

3. Student, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic)

Abstract

Chronic pancreatitis (CP) is a progressive, irreversible inflammatory disease of the pancreas characterised by fibrosis, destruction of exocrine and endocrine tissue, and a variable clinical course. Its hallmark clinical features are recurrent or persistent abdominal pain, exocrine insufficiency with maldigestion, and endocrine failure leading to pancreatogenic (type 3c) diabetes. Alcohol and smoking are the commonest risk factors in adults. Management is multidisciplinary and aims at relieving pain, correcting pancreatic insufficiency, treating complications, and slowing disease progression. This article reviews the clinical manifestations of chronic pancreatitis and outlines the general principles of medical, endoscopic and surgical treatment.

Keywords: chronic pancreatitis, abdominal pain, steatorrhoea, pancreatic enzyme replacement therapy, endoscopic therapy, pancreatic surgery

1. Introduction

Chronic pancreatitis is a long-standing inflammatory disorder in which repeated injury leads to replacement of normal pancreatic parenchyma by fibrous tissue, ductal changes (strictures, dilatation, calculi) and progressive loss of function. Reported incidence is roughly 5 to 10 new cases per 100,000 population per year, with a male predominance in alcohol-related disease. The condition significantly reduces quality of life, causes chronic disability, and is associated with increased mortality, partly from complications and partly from coexisting alcohol and tobacco use. It also carries a raised long-term risk of pancreatic adenocarcinoma.

2. Aetiology and Pathogenesis

The risk factors are conveniently remembered by the TIGAR-O classification:

•       T - Toxic-metabolic: alcohol (the most common cause), smoking, hypercalcaemia, hyperlipidaemia (hypertriglyceridaemia), chronic renal failure, medications

•       I - Idiopathic: early-onset and late-onset forms; tropical calcific pancreatitis in parts of Asia and Africa

•       G - Genetic: mutations in PRSS1 (cationic trypsinogen), SPINK1, CFTR and CTRC

•       A - Autoimmune: type 1 (IgG4-related) and type 2 (idiopathic duct-centric)

•       R - Recurrent and severe acute pancreatitis (necrosis-fibrosis sequence)

•       O - Obstructive: pancreas divisum, sphincter of Oddi dysfunction, duct strictures, tumours

The sentinel acute pancreatitis event (SAPE) hypothesis proposes that an initial acute injury attracts inflammatory cells in a susceptible patient, and persistent exposure to the causative agent (for example alcohol) drives stellate cell activation, collagen deposition and permanent fibrosis. Ductal obstruction by protein plugs and calcified stones raises intraductal pressure, and ischaemia and neural inflammation contribute to pain.

3. Symptomatology

The clinical presentation depends on the stage of disease. Early disease is dominated by pain; late disease is dominated by functional failure.

3.1 Abdominal pain

Pain is the principal and most disabling symptom, present in about 80-90% of patients. The pain profile described reflects the neuro-anatomical and pathophysiological characteristics of severe pancreatic inflammation, typical of chronic pancreatitis and recurrent acute pancreatic flares. The anatomical location of the pain centers primarily in the epigastrium, reflecting the retroperitoneal position of the pancreas and its shared visceral innervation from the celiac plexus. Because the organ lies directly anterior to the prevertebral fascia and splanchnic nerve networks, the pain frequently radiates straight through to the back in a belt-like distribution. Radiation to the left upper quadrant or the left shoulder can also occur, driven by secondary inflammation of the pancreatic tail, irritation of the left hemidiaphragm, or localized peripancreatic fluid tracking.

The character and pattern of the pain distinguish pancreatic pathology from the paroxysmal, mechanical discomfort seen in biliary disease. Pancreatic pain is classically characterized as deep, boring, steady, and unrelenting, contrasting sharply with the waxing-and-waning nature of true colicky pain. Symptom patterns vary based on the extent of parenchymal damage and neural sensitization; it may present episodically as discrete, intense attacks lasting from several hours to several days that closely mimic acute pancreatitis, or evolve into a constant, low-grade background ache punctuated by sharp, high-intensity exacerbations.

Exacerbating factors correspond directly to functional demands placed on pancreatic exocrine secretion and local tissue perfusion. Postprandial aggravation, particularly following heavy or high-fat meals, occurs as cholecystokinin and secretin stimulate acinar and ductal secretion against obstructed, fibrotic, or high-pressure pancreatic ducts. Alcohol consumption acts as a potent aggravating trigger by inducing direct acinar toxicity, increasing ductal protein concentration, and provoking transient spasm of the sphincter of Oddi, which further increases intraductal pressure and parenchymal ischemia.

Relieving postures and thermal applications leverage spatial biomechanics and sensory gating to reduce pain intensity. Leaning forward, sitting upright, or adopting a curled fetal position shifts the stomach and transverse colon anteriorly, relieving direct mechanical compression of the inflamed retroperitoneal pancreas against the spine and celiac plexus. Applying local heat to the anterior abdomen acts via thermal neuro-inhibition and cutaneous vasodilation to alleviate secondary visceral and muscular guarding.

Associated gastrointestinal and metabolic manifestations arise from delayed gastric emptying, altered autonomic tone, and fear of pain. Persistent nausea and vomiting reflect autonomic reflex pathways triggered by severe retroperitoneal inflammation. Over time, the consistent association between food ingestion and severe postprandial pain leads to profound sitophobia (fear of eating), which, combined with secondary exocrine pancreatic insufficiency and malabsorption, drives progressive weight loss and protein-calorie malnutrition.

Pain tends to lessen in some patients as the gland burns out, but this is unpredictable and should not be relied upon. Pain mechanisms are multifactorial: ductal hypertension, parenchymal ischaemia, pancreatic neuropathy with central sensitisation, and complications such as pseudocyst or duodenal obstruction.

3.2 Exocrine insufficiency

Steatorrhea and intestinal malabsorption signify advanced exocrine pancreatic insufficiency, occurring when functional lipase output drops below ten percent of normal physiological capacity. Under these conditions, unabsorbed dietary triglycerides remain within the intestinal lumen, producing characteristic stools that are pale, unusually bulky, greasy, and foul-smelling. These lipid-laden stools routinely float due to trapped gas generated by bacterial fermentation and adhere to the toilet bowl, making them notably difficult to flush.

The metabolic consequences of impaired fat and protein digestion extend across systemic energy balance and nutrient absorption. Patients experience progressive weight loss and protein-calorie malnutrition despite maintaining an adequate or even increased appetite, as the digestive machinery fails to break down and assimilate ingested macronutrients. Concurrently, unabsorbed fatty acids reach the colon, where colonic bacteria hydroxylate them into secretory secretagogues. This mechanism, combined with osmotic effects, provokes chronic diarrhea, severe abdominal bloating, and excessive flatulence.

Failure of luminal lipid digestion impairs the micellar solubilization required to absorb fat-soluble vitamins, leading to distinct systemic deficiency states:

• Vitamin A deficiency: Impairs rhodopsin regeneration within the retina, presenting clinically as night blindness (nyctalopia), xerophthalmia, and follicular hyperkeratosis.

• Vitamin D deficiency: Disrupts intestinal calcium and phosphate absorption, driving secondary hyperparathyroidism, bone demineralization, osteopenia, osteoporosis, and osteomalacia.

• Vitamin E deficiency: Triggers spinocerebellar ataxia, peripheral neuropathy, hemolytic anemia, and impaired neuromuscular coordination due to elevated oxidative cellular stress.

• Vitamin K deficiency: Inhibiting post-translational gamma-carboxylation of hepatic clotting factors (II, VII, IX, and X) causes a prolonged prothrombin time, easy mucosal bruising, epistaxis, and an elevated risk of spontaneous bleeding.

In a subset of patients, concurrent vitamin B12 (cobalamin) deficiency develops alongside fat malabsorption. Gastric haptocorrin normally binds cobalamin in the stomach, requiring cleavage by pancreatic proteases (specifically trypsin) within the duodenum so that B12 can bind intrinsic factor for ileal absorption. When pancreatic protease secretion is markedly diminished, the haptocorrin-cobalamin complex remains intact, preventing intrinsic factor binding and causing B12 malabsorption that can manifest as megaloblastic anemia or subacute combined degeneration of the spinal cord.

3.3 Endocrine insufficiency

Loss of islet cells results in impaired glucose tolerance and eventually diabetes (type 3c or pancreatogenic diabetes), usually appearing late, about 10-20 years after onset. Both insulin and glucagon are deficient, so patients are prone to brittle control with hypoglycaemia, and are often relatively insulin-sensitive. Microvascular complications can develop as in other forms of diabetes.

3.4 Other symptoms and signs

Physical signs in advanced chronic pancreatic disease reflect a combination of systemic metabolic exhaustion, localized structural compression of adjacent organs, retroperitoneal cyst formation, and shared toxic etiologies. Systemic energy failure manifests as progressive weight loss, cachexia, and generalized muscle wasting. This severe nutritional decline stems from the interplay of persistent sitophobia due to postprandial pain, uncorrected malabsorption from exocrine pancreatic insufficiency, and a hypermetabolic systemic state driven by chronic low-grade tissue inflammation. Over time, loss of skeletal muscle mass and adipose reserves impairs physical functional capacity and immune competence.

Anatomical relationship of the pancreatic head to the biliary and upper gastrointestinal tracts accounts for major compressive physical findings. Fibrotic enlargement of the pancreatic head, localized inflammation, or pseudocysts can cause intrinsic compression or stricturing of the intrapancreatic common bile duct, leading to progressive obstructive jaundice characterized by scleral icterus, dark urine, and pale stools. Similarly, mechanical distortion or extrinsic stenosis of the descending duodenum—or direct compression from a large anteriorly expanding pseudocyst—impairs normal gastric emptying, presenting clinically with persistent nausea, early satiety, and postprandial vomiting of undigested food.

Palpation of the abdomen often demonstrates a marked dissociation between subjective pain intensity and objective physical signs. Mild epigastric tenderness is common, but deep physical findings are frequently sparse or unremarkable relative to the excruciating retroperitoneal pain described by the patient, as the organ lacks direct somatic peritoneal innervation. However, when a pancreatic pseudocyst reaches significant proportions, it may present on examination as a smooth, firm, rounded, and sometimes tender abdominal mass palpable in the epigastrium or left upper quadrant.

In cases where alcohol misuse serves as the underlying driver of chronic pancreatitis, physical evaluation frequently reveals concomitant extra-pancreatic stigmata. Patients may display features of chronic alcohol dependence alongside physical signs of concurrent alcoholic liver disease, including spider angiomata, palmar erythema, parotid gland hypertrophy, Dupuytren's contracture, or subtle manifestations of early portal hypertension such as splenomegaly.

3.5 Complications

1. Pseudocyst - the commonest local complication, which may cause pain, infection, haemorrhage or rupture

2. Biliary obstruction - distal common bile duct stricture, cholestasis or cholangitis

3. Duodenal obstruction - causing gastric outlet obstruction

4. Vascular complications - splenic vein thrombosis with left-sided (sinistral) portal hypertension and gastric varices; pseudoaneurysm formation with haemorrhage

5. Pancreatic ascites and pleural effusion - due to ductal disruption

6. Metabolic bone disease - osteoporosis and fractures

7. Pancreatic adenocarcinoma - risk is increased, particularly in long-standing disease and hereditary pancreatitis

8. Opioid dependence and psychosocial problems

4. Brief Note on Diagnosis

Diagnosis rests on clinical features combined with imaging evidence of structural change. Serum amylase and lipase are often normal in established disease and are of little diagnostic value outside acute flares. Useful investigations include:

•       Plain abdominal radiograph and ultrasound: pancreatic calcification, ductal dilatation (limited sensitivity)

•       Contrast-enhanced CT: calcification, ductal dilatation, atrophy, pseudocysts

•       MRI/MRCP: ductal anatomy and strictures; secretin-enhanced MRCP improves assessment

•       Endoscopic ultrasound (EUS): the most sensitive test for early parenchymal and ductal changes

•       Faecal elastase-1: a simple non-invasive test for exocrine insufficiency (low level, below about 200 micrograms per gram of stool)

•       Fasting glucose and HbA1c: screening for diabetes

•       Serum IgG4: if autoimmune pancreatitis is suspected

Malignancy must always be considered in patients with a pancreatic mass, new stricture, rapid weight loss or new-onset diabetes in later life.

5. General Principles of Treatment

There is no cure for established chronic pancreatitis. Treatment is directed at removing the cause, relieving pain, correcting insufficiency, managing complications and improving quality of life. Care is best delivered by a multidisciplinary team including a gastroenterologist, pancreatic surgeon, radiologist, dietitian, pain specialist, endocrinologist and psychologist or addiction specialist.

5.1 Lifestyle and general measures

Non-pharmacological management and conservative lifestyle measures constitute the primary therapeutic foundation for chronic pancreatitis, directly altering the long-term clinical trajectory, suppressing disease progression, and mitigating nutritional deterioration. Alcohol cessation represents the single most critical intervention in the long-term management of chronic pancreatitis, regardless of whether ethanol was the primary underlying trigger. Complete and permanent abstinence significantly reduces the frequency and intensity of painful exacerbations, slows the structural decline of functional acinar and ductal tissue, decreases the rate of parenchymal calcification, and substantially lowers overall mortality. Given the complex nature of alcohol dependency, structured medical approaches—including brief clinical interventions, formal psychological counseling, behavioral therapy, and specialized addiction treatment services—must be systematically integrated into the care plan. 

Smoking cessation is an equally essential, independent lifestyle requirement. Tobacco smoke acts as a potent, dose-dependent synergistic toxin that accelerates pancreatic parenchymal fibrosis, speeds the development of intraductal calcifications, and exponentially raises the baseline risk of pancreatic ductal adenocarcinoma. Clinicians must offer active smoking cessation support, including pharmacotherapy and behavioral guidance, to halt this accelerated tissue destruction. 

Dietary strategy focuses on maintaining adequate caloric density while reducing functional stress on the exocrine pancreas. Patients are advised to consume small, frequent, nutrient-balanced meals throughout the day rather than a few large feedings, which reduces peak postprandial secretin and cholecystokinin release. Strict low-fat diets are explicitly contraindicated because they exacerbate preexisting protein-calorie malnutrition and impair the absorption of essential fat-soluble vitamins; instead, fat intake should remain normal to only moderately restricted, fully covered by exogenous pancreatic enzyme replacement therapy. In cases of persistent fat malabsorption or severe weight loss, medium-chain triglycerides can be incorporated as a supplemental calorie source, as they are absorbed directly across the enterocyte membrane into the portal circulation without requiring luminal pancreatic lipase or bile salt micellar solubilization. 

Systematic nutritional support is mandatory to prevent and manage the severe cachexia and micronutrient depletion associated with advanced disease. Initial management requires comprehensive baseline and ongoing assessments by a specialized dietitian. When standard oral intake fails to meet calculated energy and protein requirements, oral nutritional supplements tailored for malabsorptive states should be introduced. If oral feeding remains inadequate due to persistent sitophobia or intractable pain, tube feeding via a nasojejunal route is the preferred enteral intervention, as post-ligament of Treitz nutrient delivery minimizes exocrine pancreatic stimulation. Total parenteral nutrition should be strictly reserved as a last resort, utilized only when enteral feeding pathways are anatomically inaccessible or functionally non-viable. 

Finally, addressing reversible metabolic triggers is necessary to prevent ongoing acinar toxic injury and recurrent inflammatory flares. Metabolic evaluation must identify and correct hypertriglyceridemia, as circulating free fatty acids generated by pancreatic lipase degradation of excess triglycerides exert direct microvascular and acinar cytotoxicity. Similarly, hypercalcemia—whether secondary to primary hyperparathyroidism or other systemic conditions—must be corrected, as elevated intra-acinar calcium concentrations prematurely convert trypsinogen to active trypsin, provoking intracellular autodigestion and sustained tissue destruction.

5.2 Pain management

Pain control follows a stepwise approach. Analgesic management of chronic pancreatic pain follows a stepwise, multimodal framework aimed at controlling retroperitoneal discomfort, targeting altered central processing, and minimizing the risks associated with long-term opioid use.  

Simple analgesics serve as the initial tier of pharmacological control for mild-to-moderate background pain. Acetaminophen (paracetamol) is utilized as a safe baseline non-opioid agent. Nonsteroidal anti-inflammatory drugs (NSAIDs) may be added to target localized inflammatory pathways, provided that renal function is preserved, portal hypertensive gastropathy or gastroesophageal varices are absent, and gastric mucosal protection is co-administered to mitigate the risk of peptic ulceration. 

Weak opioids represent the next step when simple analgesics prove insufficient for daily pain management. Tramadol is widely preferred in this context due to its dual mechanism of action: mild mu-opioid receptor agonism combined with the inhibition of norepinephrine and serotonin reuptake. This dual pathway provides effective visceral analgesia while carrying a lower risk of dependence and gastrointestinal dysmotility compared to conventional opioids. 

Neuromodulators act as crucial adjuvant agents to address the central sensitization and neurogenic remodeling that develop during chronic pancreatic inflammation. Persistent damage to celiac plexus nerve fibers leads to neuropathic pain states characterized by hyperalgesia and allodynia. Pregabalin, gabapentin, and low-dose tricyclic antidepressants (such as amitriptyline) modulate altered nociceptive signaling at the spinal cord and central levels, enhancing pain control and reducing total opioid consumption. 

Strong opioids are reserved for severe, refractory pain or acute exacerbations, but their administration must be strictly controlled and limited to short periods. Prolonged usage carries a high risk of physiological dependence, tolerance, and addiction. Furthermore, chronic strong opioid therapy frequently precipitates narcotic bowel syndrome—a paradox where high-dose opioids worsen abdominal pain by causing severe intestinal dysmotility, sphincter of Oddi spasm, and delayed gastrointestinal transit.  

Unconventional and biochemical therapies are sometimes integrated into early pain protocols, though their efficacy varies. High-dose pancreatic enzyme replacement therapy aims to suppress endogenous pancreatic secretion via a negative feedback loop; by delivering active trypsin to the duodenum, it cleaves cholecystokinin-releasing factor, lowering circulating cholecystokinin levels and resting ductal pressure. However, clinical evidence supporting enzymes specifically for pain relief remains inconsistent, showing greater benefit in non-calcific disease. Similarly, oral antioxidant regimens targeting reactive oxygen species and oxidative acinar stress have been extensively studied, but high-quality clinical trials demonstrate only weak or conflicting evidence regarding sustained pain reduction. 

Interventional neurolytic techniques offer a non-pharmacological avenue for refractory cases, though their therapeutic duration is inherently limited. Percutaneous, endoscopic ultrasound-guided, or surgical celiac plexus block interrupts visceral pain conduction by injecting local anesthetics and corticosteroid or neurolytic agents directly around the celiac ganglion. While this procedure can achieve significant short-term pain attenuation, its therapeutic effect typically wanes within three to six months as neural pathways regenerate or collateral nociceptive fibers recruit, necessitating careful patient selection.

Treatable causes of pain, including pseudocyst, duct obstruction, duodenal stenosis, and pancreatic cancer, should be actively sought. Patients with refractory pain should be assessed early for endoscopic or surgical intervention rather than escalating opioids.

5.3 Treatment of exocrine insufficiency

Pancreatic enzyme replacement therapy (PERT) is indicated for steatorrhoea, weight loss or documented malabsorption.

• Use enteric-coated, pH-sensitive microsphere preparations

• Typical starting dose is about 40,000-50,000 units of lipase with each main meal and about half that with snacks, titrated according to symptoms and nutritional status

• Capsules are taken with meals, ideally swallowed in divided portions during the meal

• Add a proton pump inhibitor if response is poor, to reduce gastric acid inactivation of enzymes

• Monitor weight, stool frequency, nutritional markers, and fat-soluble vitamin levels; supplement vitamins A, D, E and K when deficient

• Assess bone density and treat osteoporosis with calcium, vitamin D and, if indicated, bisphosphonates

5.4 Management of endocrine insufficiency

Diabetes is managed with dietary advice, and most patients eventually require insulin. Metformin may be used in early or mild disease. Hypoglycaemia is a particular risk because of glucagon deficiency and poor nutrition, so targets are individualised and patients need education on hypoglycaemia. Regular screening for microvascular complications is required.

5.5 Endoscopic treatment

Endoscopic and minimally invasive interventional strategies provide targeted mechanical clearance, decompression, and drainage in chronic pancreatitis, bridging conservative medical management and major open surgical reconstruction. Endoscopic retrograde cholangiopancreatography (ERCP) with specialized pancreatic duct interventions addresses intraductal hypertension driven by mechanical obstruction. Pancreatic sphincterotomy reduces basal resistance at the major or minor papilla, facilitating stone extraction and improving fluid flow. When intraductal calculi exceed the diameter of the main pancreatic duct or are impacted behind fibrotic strictures, extracorporeal shock wave lithotripsy (ESWL) is utilized to focus acoustic energy directly onto the calcifications. ESWL fragments these large intraductal stones into micro-calculi, which are subsequently cleared via follow-up ERCP retrieval baskets or balloon catheters to restore ductal patency. For dominant main pancreatic duct strictures causing upstream dilation, endoscopic serial balloon dilation followed by temporary stenting relieves localized high-pressure zones and promotes ductal remodeling. 

Interventions on the biliary tree mitigate secondary compressive complications arising from chronic peripancreatic inflammation and fibrotic head mass formation. Symptomatic intrapancreatic common bile duct strictures, which manifest with cholestasis or ascending cholangitis, are treated with endoscopic biliary stenting. The deployment of fully covered self-expandable metal stents (FCSEMS) is preferred over plastic stents for long-standing benign biliary strictures, as they offer superior radial force, maintain lumen diameter over extended periods, and drastically reduce the re-intervention rate by preventing tissue ingrowth through the stent mesh. 

Endoscopic transmural drainage serves as the standard of care for mature, symptomatic pancreatic pseudocysts and walled-off necrosis located adjacent to the upper gastrointestinal tract. Utilizing real-time endoscopic ultrasound (EUS) guidance, clinicians puncture the gastric or duodenal wall directly into the pseudocyst cavity, avoiding overlying intercavitary vascular structures. Creation of a cystogastrostomy or cystoduodenostomy tract is consolidated by placing lumen-apposing metal stents (LAMS) or double-pigtail plastic stents. This internal drainage pathway allows the high-pressure cyst contents to empty directly into the stomach or duodenum, leading to cavity collapse, resolution of localized mass effect, and avoidance of external cutaneous fistulae.

Endoscopic therapy is less invasive and carries lower immediate risk, but long-term pain relief is less durable than with surgery in many series, and repeated procedures may be needed.

5.6 Surgical treatment

Surgery is considered when there is intractable pain, failure of endoscopic therapy, suspicion of malignancy, or complications that cannot be managed endoscopically. Randomised trials have shown better and more durable pain relief with surgery than with endoscopy in selected patients with a dilated duct, and recent evidence supports earlier consideration of surgery rather than prolonged delay. Operations are chosen according to anatomy.

Surgery relieves pain in the majority of patients but does not restore pancreatic function, and new or worsening exocrine and endocrine insufficiency may follow.

5.7 Treatment of specific complications

Management of local complications in chronic pancreatitis requires a tailored combination of conservative observation, endovascular therapy, endoscopic drainage, and surgical reconstruction, dictated by the specific mechanical, vascular, or secretory anomaly present. 

Pancreatic pseudocysts are mature, fluid-filled collections lacking an epithelial lining that arise from chronic ductal disruption or peripancreatic fluid collection. Asymptomatic pseudocysts that are small (typically under six centimeters) and remain stable on longitudinal imaging require observation only, as many resolve spontaneously over time. Intervention becomes imperative when a pseudocyst grows rapidly, causes symptoms such as chronic pain or early satiety, becomes secondarily infected, or compresses adjacent vascular and visceral structures. Endoscopic transmural drainage via EUS-guided cystogastrostomy or cystoduodenostomy serves as the primary treatment modality. Percutaneous image-guided drainage is reserved for infected fluid collections or fluid tracking outside the reach of the stomach and duodenum, while formal surgical drainage (such as a Roux-en-Y cystojejunostomy) is reserved for complex, multiloculated cysts or failed endoscopic approaches. 

Biliary obstruction secondary to fibrotic stricturing of the intrapancreatic common bile duct presents a progressive threat of secondary biliary cirrhosis and ascending cholangitis. Endoscopic placement of temporary biliary stents—ideally fully covered self-expandable metal stents—provides immediate luminal clearance and relieves cholestasis during acute inflammatory flares. However, if the biliary stricture remains persistent, rigid, or recurrent after repeated stenting trials, definitive surgical biliary bypass is indicated. A Roux-en-Y hepaticojejunostomy or choledochoduodenostomy bypasses the fibrotic pancreatic head entirely, establishing long-term, low-pressure biliary drainage. 

Splenic vein thrombosis develops as a direct consequence of persistent retroperitoneal inflammation around the splenic vasculature, giving rise to left-sided, non-cirrhotic portal hypertension. Thrombosis of the splenic vein forces collateral venous blood from the spleen to drain through the short gastric and gastroepiploic veins toward the portal vein, resulting in isolated gastric varices. While asymptomatic left-sided portal hypertension requires no immediate intervention, active or prior gastrointestinal hemorrhage from gastric varices necessitates surgical splenectomy. Splenectomy severs the hyperdynamic venous flow feeding the short gastric collaterals, effectively curing this localized form of portal hypertension. 

Pseudoaneurysm formation represents a life-threatening vascular complication caused by enzymatic erosion of peripancreatic arteries—most commonly the splenic, gastroduodenal, or inferior pancreaticoduodenal arteries—by activated pancreatic secretions or adjacent pseudocyst contents. Rupture into a pseudocyst, the pancreatic duct (hemosuccus pancreaticus), or the free peritoneal cavity triggers severe gastrointestinal or intra-abdominal hemorrhage. Urgent transcatheter angiographic embolization with microcoils or covered stents is the first-line treatment to achieve immediate hemostasis. Surgical ligation or excision is reserved for cases where endovascular embolization fails, is anatomically unfeasible, or when the patient is hemodynamically unstable. 

Pancreatic ascites and pancreatic pleural effusions occur when an unhealed disruption of a major or minor pancreatic duct leads to continuous leakage of pancreatic secretions, which track anteriorly into the peritoneal cavity or retroperitoneally through the aortic or esophageal hiatus into the pleural space. Initial conservative management focuses on reducing exocrine pancreatic secretion through complete bowel rest, total parenteral nutrition, and continuous administration of somatostatin analogs such as octreotide. Transpapillary ERCP with pancreatic duct stenting is deployed to bridge the disruption point, decompressing ductal pressure and facilitating tissue healing. If internal ductal leakage persists despite conservative and endoscopic measures, surgical repair—typically via distal pancreatic resection or a Roux-en-Y pancreaticojejunostomy over the disruption site—is required.

5.8 Follow-up

Long-term follow-up should cover nutritional status, glycaemic control, bone health, psychosocial wellbeing, alcohol and smoking abstinence, and awareness of cancer. New or changed symptoms such as weight loss, jaundice or altered pain pattern require prompt investigation to exclude malignancy.

6. Conclusion

Chronic pancreatitis is a progressive condition in which pain, maldigestion and diabetes dominate the clinical picture. Recognition of its characteristic symptoms allows earlier diagnosis and prevention of complications. Treatment is stepwise and individualised: lifestyle modification, particularly abstinence from alcohol and tobacco, forms the foundation; analgesia and enzyme replacement control symptoms; endoscopic therapy and surgery are reserved for obstruction, refractory pain and complications. A multidisciplinary approach gives the best outcomes in this chronic and challenging disease.

References

1.     Majumder S, Chari ST. Chronic pancreatitis. Lancet. 2016;387(10031):1957-1966.

2.     Kleeff J, Whitcomb DC, Shimosegawa T, et al. Chronic pancreatitis. Nat Rev Dis Primers. 2017;3:17060.

3.     Löhr JM, Dominguez-Munoz E, Rosendahl J, et al. United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU). United European Gastroenterol J. 2017;5(2):153-199.

4.     Gardner TB, Adler DG, Forsmark CE, Sauer BG, Taylor JR, Whitcomb DC. ACG Clinical Guideline: Chronic Pancreatitis. Am J Gastroenterol. 2020;115(3):322-339.

5.     Williams NS, O'Connell PR, McCaskie AW (eds). Bailey and Love's Short Practice of Surgery. 28th ed. CRC Press; chapter on the pancreas.

6.      Kumar P, Clark M. Kumar and Clark's Clinical Medicine. Chapter on pancreatic disease.